Shionogi (TYO:4507) said Taiwan's Food and Drug Administration accepted the new drug application for ensitrelvir fumaric acid submitted by its Taiwanese subsidiary.
A contract for purchasing ensitrelvir for government stockpiling was also finalized with the Taiwan Centers for Disease Control, according to a Wednesday bourse filing.
Ensitrelvir is an oral antiviral that inhibits SARS-CoV-2 replication, and while it has full approval in Japan and special access in Singapore, it remains investigational elsewhere.
Price (JPY): $2263.00, Change: $+31, Percent Change: +1.39%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。